WO2009090556A3 - Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a - Google Patents

Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a Download PDF

Info

Publication number
WO2009090556A3
WO2009090556A3 PCT/IB2009/000468 IB2009000468W WO2009090556A3 WO 2009090556 A3 WO2009090556 A3 WO 2009090556A3 IB 2009000468 W IB2009000468 W IB 2009000468W WO 2009090556 A3 WO2009090556 A3 WO 2009090556A3
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
tobacco
market
addictive
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/000468
Other languages
English (en)
Other versions
WO2009090556A2 (fr
WO2009090556A8 (fr
Inventor
Jean-Pol Tassin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TASSIN THOMAS
Original Assignee
TASSIN THOMAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TASSIN THOMAS filed Critical TASSIN THOMAS
Publication of WO2009090556A2 publication Critical patent/WO2009090556A2/fr
Publication of WO2009090556A8 publication Critical patent/WO2009090556A8/fr
Publication of WO2009090556A3 publication Critical patent/WO2009090556A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention permet non seulement aux fumeurs d'arrêter de consommer du tabac, sans limitation de durée et sans encourir d'effets indésirables importants, mais aussi aux consommateurs de drogues toxicomanogènes en général (opiacés, psychostimulants, alcool) d'arrêter la consommation des drogues concernées. CONTEXTE DE L'INVENTION. Sur le marché, les produits utilisés dans la lutte contre le tabagisme sont de trois types : a. les apports de nicotine (patch, gomme à mâcher...) : La nicotine n' a pas d' effet toxique mais les apports de nicotine seule n'ont un effet significatif sur la consommation de tabac que pendant les premières semaines de traitement. Les rechutes sont très fréquentes (supérieures à 75 %). b. le Zyban (Bupropion) : Le Zyban, consommé avec ou sans nicotine, n'agit pas comme un substitut addictif. Sur le plan clinique, on constate 80% de rechute après un mois de traitement. Il a de plus des effets cardiovasculaires indésirables. c. le Champix (la Varénicline): Le Champix est de commercialisation récente. Il a pour fonction d'inhiber en partie l'effet de la nicotine. Il n'agit pas comme substitut addictif. Sur le plan clinique, les taux d'arrêt communiqués jusqu'à présent sont de l'ordre de 44% après un mois, avec des niveaux de rechute dans les mois qui suivent très importants. Des effets secondaires non négligeables tels que les troubles du sommeil sont décrits depuis sa mise sur le marché. Les principales recherches actuel
PCT/IB2009/000468 2008-01-14 2009-03-09 Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a Ceased WO2009090556A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR08/00189 2008-01-14
FR0800189A FR2926221A1 (fr) 2008-01-14 2008-01-14 Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.

Publications (3)

Publication Number Publication Date
WO2009090556A2 WO2009090556A2 (fr) 2009-07-23
WO2009090556A8 WO2009090556A8 (fr) 2009-10-01
WO2009090556A3 true WO2009090556A3 (fr) 2010-01-07

Family

ID=39671393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/000468 Ceased WO2009090556A2 (fr) 2008-01-14 2009-03-09 Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a

Country Status (2)

Country Link
FR (1) FR2926221A1 (fr)
WO (1) WO2009090556A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023796A1 (fr) * 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox destiné au traitement de l'addiction
IN2015MN00002A (fr) 2012-07-09 2015-10-16 Lupin Ltd
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642787A2 (fr) * 1993-09-09 1995-03-15 Eli Lilly And Company Moyen pour se désaccostumer du tabac
WO2003039518A1 (fr) * 2001-11-02 2003-05-15 Smithkline Beecham Corporation Preparations orales a liberation lente utilisees pour reduire ou empecher les etats de manque de nicotine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
AU1810501A (en) * 2000-12-01 2002-06-11 Be Able Llc Behavior chemotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642787A2 (fr) * 1993-09-09 1995-03-15 Eli Lilly And Company Moyen pour se désaccostumer du tabac
WO2003039518A1 (fr) * 2001-11-02 2003-05-15 Smithkline Beecham Corporation Preparations orales a liberation lente utilisees pour reduire ou empecher les etats de manque de nicotine

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEETA SURVJIT ET AL: "The dorsal raphe nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses", PSYCHOPHARMACOLOGY, vol. 155, no. 1, April 2001 (2001-04-01), pages 78 - 85, XP002537144, ISSN: 0033-3158 *
CHEETA SURVJIT ET AL: "The role of 5-HT1A receptors in mediating the anxiogenic effects of nicotine following lateral septal administration", EUROPEAN JOURNAL OF NEUROSCIENCE, OXFORD UNIVERSITY PRESS, GB, vol. 12, no. 10, 1 October 2000 (2000-10-01), pages 3797 - 3802, XP009106393, ISSN: 0953-816X *
FILE S E ET AL: "The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 66, no. 1, 1 January 2000 (2000-01-01), pages 65 - 72, XP008108269, ISSN: 0091-3057 *
KENNY PAUL J ET AL: "Anxiogenic effects of nicotine in the dorsal hippocampus are mediated by 5-HT1A and not by muscarinic M1 receptors", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 39, no. 2, 4 January 2000 (2000-01-04), pages 300 - 307, XP002502344, ISSN: 0028-3908 *
LANTERI CHRISTOPHE ET AL: "Inhibition of Monoamine Oxidases Desensitizes 5-HT1A Autoreceptors and Allows Nicotine to Induce a Neurochemical and Behavioral Sensitization", JOURNAL OF NEUROSCIENCE, vol. 29, no. 4, January 2009 (2009-01-01), pages 987 - 997, XP008108240, ISSN: 0270-6474 *
MA Z ET AL: "Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats", NEUROSCIENCE, NEW YORK, NY, US, vol. 135, no. 3, 1 January 2005 (2005-01-01), pages 949 - 958, XP025367213, ISSN: 0306-4522, [retrieved on 20050101] *
NADER M A ET AL: "Interactions of buspirone or gepirone with nicotine on schedule-controlled behavior of pigeons", BEHAVIOURAL PHARMACOLOGY, RAPID SCIENCE, PUBLISHERS, GB, vol. 4, no. 3, 1 June 1993 (1993-06-01), pages 263 - 268, XP008113373, ISSN: 0955-8810 *
OLAUSSON P ET AL: "Effects of 8-OH-DPAT and DOI on the expression of locomotor sensitization and behavioral disinhibition after repeated nicotine treatment", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, & 30TH ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 04-09, 2000, pages Abstract No. - 192.7, XP002552447, ISSN: 0190-5295 *
SCHRÖR K ET AL: "Augmented myocardial ischaemia by nicotine--mechanisms and their possible significance.", BRITISH JOURNAL OF PHARMACOLOGY SEP 1998, vol. 125, no. 1, September 1998 (1998-09-01), pages 79 - 86, XP002537145, ISSN: 0007-1188 *
SUEMARU K ET AL: "Effects of .beta.-adrenergic receptor antagonists on nicotine -induced tail tremor in rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 46, no. 1, 1 January 1993 (1993-01-01), pages 131 - 133, XP008094863, ISSN: 0091-3057 *

Also Published As

Publication number Publication date
FR2926221A1 (fr) 2009-07-17
WO2009090556A2 (fr) 2009-07-23
WO2009090556A8 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
Valente et al. Khat and synthetic cathinones: a review
WO2007056284A3 (fr) Compositions viscoelastiques polycationiques
WO2008132600A3 (fr) Antagonistes de trpv1 et utilisations de ceux-ci
DK1458252T3 (da) Tobak og/eller tobak i kombination med tobakssubstitutkomposition til anvendelse som snus i den orale kavitet
TW200621722A (en) 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20140261485A1 (en) Inhibition of sensory irritation during consumption of smokeless tobacco products using a combinatorial approach
SG171601A1 (en) Further medical uses of antisecretory protein
Kichko et al. Bimodal concentration-response of nicotine involves the nicotinic acetylcholine receptor, transient receptor potential vanilloid type 1, and transient receptor potential ankyrin 1 channels in mouse trachea and sensory neurons
WO2008089201A3 (fr) Composés de pipéridine substituée hétérocycliques et leurs utilisations
WO2007070504A3 (fr) Compositions orales liquides de sumatriptan stables et de gout agreable
Van der Kam et al. Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat
WO2009090556A8 (fr) Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d&#39; autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d&#39;un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a
KR20100028182A (ko) 전자 담배용 니코틴 수용액
Hussmann et al. Chronic sazetidine‐A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain
MX2008013777A (es) Usos medicos adicionales de la proteina antisecretora.
SE9904413D0 (sv) Comminuted form
US20180132522A1 (en) Additives for tobacco cut filler
CN102917609A (zh) 可分解的栓塞包装及其应用
WO2008010863A3 (fr) Nouveau substitut de tabac
WO2005113012A3 (fr) Compositions et procedes pour moduler la masse osseuse
Lewis et al. Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type
WO2007083196A3 (fr) Incorporation de composes de liberation d&#39;ammoniac dans des articles de tabac
JP2006217820A (ja) シガレット
Villégier et al. Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self‐administration
MD3584G2 (ro) Procedeu de hrănire complementară a animalelor paricopitate sălbatice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09702033

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09702033

Country of ref document: EP

Kind code of ref document: A2